Abstract 108P
Background
The human epidermal growth factor receptor 2 (HER2/neu) play a predictive and prognostic role in colorectal cancer (CRC). Accurate evaluating of HER2 overexpression is required for selection and determination of eligible patients for HER2-directed therapy or primary resistance and poor response to anti-EGFR therapy. However, there is no currently established best practice for HER2 testing and interpretation in CRC. The purpose of this study was to validate and evaluate the performance of AmoyDx® HANDLE Classic NGS Panel (CP40) in assessing HER2 status by comparing it with HER2 IHC (4B5)/FISH analysis.
Methods
The CP40 is based on Halo-shape ANnealing and Defer-Ligation Enrichment (HANDLE) system technology, which allows high sensitivity in 40 key solid tumour genes qualitative detection and microsatellite instability (MSI) status assessment utilizing DNA and RNA. Performance of the CP40 was compared against the HER2 IHC/FISH assay according to the HERACLES scoring criteria using 805 CRC samples. Only samples with a ratio ERBB2:CEN17 ≥ 2 or staining equivocal (2+) or positive (3+) in at least 50% of cells were determined as HER2 IHC/FISH positive.
Results
CP40 and IHC/FISH assays were highly concordant in their assessment of HER2 status in CRCs (99.50%, 801/805, kappa = 0.892). Three conflicting results were negative in CP40 but were scored 2+ in 50-70% of the cells and identified as positive by IHC/FISH. One CRC scored as 3+ in 40% cells was determined to be negative by both CP40 and IHC/FISH. And all MSI CRCs were evaluated as HER2 negative by both CP40 and IHC. Table: 108P
Comparison of HER2 status determined from CP40 and IHC/FISH assays
| ERBB2 NGS-based CNV testing | ||||
| True | False | Total | ||
| HER2 IHC/FISH assay | Positive | 17 | 3 | 20 |
| Negative | 1 | 784 | 785 | |
| Total | 18 | 787 | 805 | |
| Kappa= | 0.892 | |||
| Overall coincidence rate = | 99.50% |
Conclusions
CRC-specific HER2 testing protocols and HER2 scoring criteria still needs to be optimised in a more refined and defined manner. HANDLE-based CP40, which combines DNA and RNA in NGS testing, is a potent tool for sensitive and reliable detection of HER2 status in clinical diagnostics.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
602P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
Presenter: Andrew Haydon
Session: Poster Display
Resources:
Abstract
603P - An individualised postoperative radiological surveillance schedule for IDH-wildtype glioblastoma patients (HK-GBM Registry)
Presenter: Jason Chak Yan Li
Session: Poster Display
Resources:
Abstract
604P - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status
Presenter: Marcia Brose
Session: Poster Display
Resources:
Abstract
606P - BRAF and NRAS mutations are associated with poor prognosis in Asians with acral-lentiginous and nodular cutaneous melanoma
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
607P - Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan
Presenter: Naoya Yamazaki
Session: Poster Display
Resources:
Abstract
608P - The efficacy of immune checkpoint inhibitors and targeted therapy in mucosal melanomas: A systematic review and meta-analysis
Presenter: Andrea Teo
Session: Poster Display
Resources:
Abstract
609P - The association between thyroid function abnormalities and vitiligo induced by pembrolizumab regarding prognosis in patients with advanced melanoma
Presenter: Moez Mobarek
Session: Poster Display
Resources:
Abstract
610P - Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation
Presenter: Charles Jeffrey Tan
Session: Poster Display
Resources:
Abstract
611P - ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)
Presenter: Thi Thao Vi Luong
Session: Poster Display
Resources:
Abstract
612P - Is the juice worth the squeeze? Overall survival gain per unit treatment time as a metric of clinical benefit of systemic treatment in incurable cancers
Presenter: Vodathi Bamunuarachchi
Session: Poster Display
Resources:
Abstract